CoChat
Sign Up
Cited by 264Schizophrenia research and treatmentNeuroscience and Neuropharmacology ResearchNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.

GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon

Guidotti, Alessandro, Auta, James, Davis, John M., Dong, Erbo, Grayson, Dennis R., Veldic, Marin, Zhang, Xianquan, Costa, Erminio·2005·Psychopharmacology
DOI 10.1007/s00213-005-2212-8
Open this paper in CoChat — free account

Abstract

Rationale Cortical gamma-aminobutyric acid (GABA)ergic neurons contribute to the orchestration of pyramidal neuron population firing as follows: (1) by releasing GABA on GABA(A) and GABA(B) receptors, (2) by releasing reelin in the proximity of integrin receptors located on cortical pyramidal neuron dendritic spines, and (3) through reelin contributing to the regulation of dendritic spine plasticity by modulating dendritic resident mRNA translation. In schizophrenia (SZ) and bipolar (BP) postmortem brains, the downregulation of mRNAs encoding glutamic acid decarboxylase 67 (GAD(67)) and reelin decreases the cognate proteins coexpressed in prefrontal cortex (PFC) GABAergic neurons. This finding has been replicated in several laboratories. Such downregulation suggests that the neuropil hypoplasticity found in the PFC of SZ and BP disorder patients may depend on a downregulation of GABAergic function, which is associated with a decrease in reelin secretion from GABAergic neuron axon terminals on dendrites, somata, or axon initial segments of pyramidal neurons. Indirectly, this GABAergic neuron downregulation may play a key role in the expression of positive and negative symptoms of SZ and BP disorders.Objectives The above described GABAergic dysfunction may be addressed by pharmacological interventions to treat SZ and BP disorders using specific benzodiazepines (BZs), which are devoid of intrinsic activity at GABA(A) receptors including alpha(1) subunits but that act as full positive allosteric modulators of GABA action at GABA(A) receptors containing alpha(2), alpha(3), or alpha(5) subunits. These drugs are expected to enhance GABAergic signal transduction without eliciting sedation, amnesia, and tolerance or dependence liabilities.Results and conclusions BZs, such as diazepam, although they are efficient in equilibrating GABA(A) receptor signal transduction in a manner beneficial in the treatment of positive and negative symptoms of SZ, may not be ideal drugs, because by mediating a full positive allosteric modulation of GABA(A) receptors containing the alpha(1) subunit, they contribute to sedation and to the development of tolerance after even a brief period of treatment. In contrast, other BZ-binding site ligands, such as 6-(2bromophenyl)-8-fluoro-4H-imidazo [1,5-a][1,4] benzodiazepine-3-carboxamide (imidazenil), which fail to allosterically and positively modulate the action of GABA at GABA(A) receptors with alpha(1) subunits but that selectively allosterically modulate cortical GABA(A) receptors containing alpha(5) subunits, contribute to the anxiolytic, antipanic, and anticonvulsant actions of these ligands without producing sedation, amnesia, or tolerance. Strong support for the use of imidazenil in psychosis emerges from experiments with reeler mice or with methionine-treated mice, which express a pronounced reelin and GAD(67) downregulation that is also operative in SZ and BP disorders. In mice that model SZ symptoms, imidazenil increases signal transduction at GABA(A) receptors containing alpha(5) subunits and contributes to the reduction of behavioral deficits without producing sedation or tolerance liability. Hence, we suggest that imidazenil may be considered a prototype for a new generation of positive allosteric modulators of GABA(A) receptors, which, either alone or in combination with neuroleptics, should be evaluated in GABAergic dysfunction operative in the treatment of SZ and BP disorders with psychosis.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00213-005-2212-8

Cites

104 of 104 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 2

  1. Costa E, Davis JM, Dong E, Grayson DR, Guidotti A, Tremolizzo L, Veldic M (2004) A GABAergic cortical deficit dominates schizophrenia pathophysiology. Crit Rev Neurobiol 16:1–24
  2. Peters A (1984) Chandelier cells. In: Jones EG, Peters A (eds) Cerebral cortex, vol 1. Plenum Press, NY, pp 361–380

Cited by

Sorted by citations

See all 264

Related

See all

Metadata

Authors
Guidotti, A., Auta, J., Davis, J. M., Dong, E., Grayson, D. R., Veldic, M., Zhang, X., & Costa, E.
Affiliations
University of Illinois Chicago (US)
Corresponding author
Costa, Erminio
ORCID
Venue
Psychopharmacology
Publisher
Springer Science and Business Media LLC
Published
2005-04-28
Volume
180
Issue
2
Pages
191-205
ISSN
  • 0033-3158 (ISSN-L)
  • 1432-2072
DOI
10.1007/s00213-005-2212-8
OpenAlex
W2072551779
Cited by
262
References
104
Citations by year
2026: 1 · 2025: 2 · 2024: 5 · 2023: 6 · 2022: 2 · 2021: 4 · 2020: 11 · 2019: 7 · 2018: 12 · 2017: 10 · 2016: 11 · 2015: 16 · 2014: 22 · 2013: 13 · 2012: 10
FWCI
2.92
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Mental Health (R01MH6262A, R01MH062188, R01MH062090, R01MH62188, R01MH62090)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
schizophrenia, bipolar disorder, GABAergic dysfunction, GABAergic interneurons, reelin, GAD67, prefrontal cortex, benzodiazepines, positive allosteric modulation, GABAA receptor, alpha1 subunit, diazepam, sedation, drug tolerance, antipsychotic drugs, dendritic spine plasticity
MeSH terms
Reelin Protein, Animals, Benzodiazepines, Bipolar Disorder, Cerebral Cortex, gamma-Aminobutyric Acid, Glutamate Decarboxylase, Humans, Nerve Tissue Proteins, Synaptic Transmission, Receptors, GABA-A, Schizophrenia, Serine Endopeptidases, Cell Adhesion Molecules, Neuronal, Extracellular Matrix Proteins, Chloride Channels

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review